APPENDICES. A systematic review and economic model of the ...

Core symptoms Educational performance Quality of life Adverse events
Analyses of safety are restricted to those
patients who took at least 1 dose of the study
drug (n = 294)
ADHD Rating Scale total:
Change from baseline to end-point – mean (SD; 95% CI
for difference from placebo) for ATX0.5/ATX1.2/ATX1.8
–9.9 (14.6; –8.9 to 0.9)/–13.6*(14.0; –12.1 to –4.0)/–13.5*
(14.5; –11.9 to –3.7
Placebo: –5.8 (10.9)
*p < 0.05 compared with placebo
ADHD Rating Scale Inattention subscale
Change from baseline to end-point – mean (SD; 95% CI
for difference from placebo) for ATX0.5/ATX1.2/ATX1.8
–5.1(7.5; –5.2 to 0.3)/–7.0* (8.1; –6.8 to –2.2)/–6.8* (7.9;
–6.6 to –2.0)
Placebo: –2.5 (6.6)
*p =